retatrutide benefits study Eli Lilly's shows promising weight loss results in phase 3 trial There's so much talk about

Only 5 patients stopped the trial from gastrointestinal side effects and only 5% of the 9mg and 12mg arms had to stop the trial for any adverse events

In addition to behavioral preservation, the study also determined that the number of synapses remained unchanged and the number of plaques and amyloid oligomers decreased, all physical indications against neurodegeneration [61]

Additional Use Cases in the Pipeline GLP-1s were a big deal for diabetes, then became a bigger deal for weight loss

Blood Sugar Control Both compounds significantly improve glycemic control with 1.5 to 2 percentage point HbA1c reductions

Mounjaro is registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates

Results will be noticeably compromised